 Induction chemotherapy: idarubicin 12mgm2day intravenous, days 1, 3 and 5, intermediate-dose cytarabine 500mgm212h, intravenous, days 1, 3 and 5 and etoposide 100mgm2day, intravenous, from day 1 to 3 as in AML-99 trial NCT01716793, with the addition of subcutaneous G-CSF from day 0 to the last day of chemotherapy. This induction therapy is repeated if complete remission CR is not achieved after the first course of treatment. 